Related Experiment Video
Updated: Oct 5, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Heart failure with mildly reduced ejection fraction: emerging frontiers in clinical characteristics, prognosis, and
Zhi Shang1, Xinyu Wang1, Wei Gao1
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, 100191 Beijing, China.
Insights
Heart failure with mildly reduced ejection fraction (HFmrEF) is now a distinct clinical classification. Emerging research suggests HFmrEF patients may benefit from therapies similar to those with lower ejection fractions.
Area of Science:
- Cardiology
- Clinical Medicine
- Heart Failure Research
Background:
- Heart failure (HF) is a major cause of morbidity and mortality.
- Previous guidelines classified HF based on ejection fraction, with a gap for mid-range values.
- The 2016 ESC guideline introduced 'heart failure with mid-range ejection fraction' (HFmREF).
Purpose of the Study:
- To review the clinical characteristics, prognosis, and treatment of HFmrEF.
- To highlight the evolution of HFmrEF classification and understanding.
- To provide guidance for clinicians managing HFmrEF patients.
Main Methods:
- Review of recent clinical studies and guidelines.
- Analysis of emerging diagnostic technologies (e.g., speckle tracking echocardiography, cardiac MRI).
- Evaluation of novel biomarkers for HF assessment.
Main Results:
- The term 'HF with mid-range ejection fraction' was updated to 'heart failure with mildly reduced ejection fraction' (HFmrEF).
- Growing evidence supports HFmrEF as a distinct entity.
- Novel technologies and biomarkers enhance HF evaluation.
Conclusions:
- HFmrEF represents a significant patient population.
- Patients with HFmrEF may respond to existing HF therapies.
- Continued research and updated guidelines are crucial for optimal HFmrEF management.
Abstract:
Heart failure (HF) is a complex clinical syndrome resulting from the impairment of ventricular filling or ejection of blood or both, leading to considerable morbidity and mortality. Based on left ventricular ejection fraction (LVEF), the 2016 European Society of Cardiology (ESC) guideline firstly classified patients with LVEF in the range of 40% to 49% into heart failure with mid-range ejection fraction. Since then, more and more clinical studies targeting HF with mid-range ejection fraction emerged, indicating that they may benefit from similar therapies to those with LVEF ≤40%. So the latest ESC guideline of HF changed the term 'heart failure with mid-range ejection fraction' to 'heart failure with mildly reduced ejection fraction' (HFmrEF). Simultaneously, burgeoning evidence indicating the emergence of novel technologies (such as speckle tracking echocardiography, cardiac magnetic resonance quantitative imaging), and new biomarkers were conducive to evaluating HF from different perspectives. In this review, we summarized the research progress of HFmrEF in clinical characteristics, prognosis, and treatment, hoping to help cardiologists better evaluate and treat patients of HFmrEF.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care

